FR11C0014I1 - - Google Patents

Info

Publication number
FR11C0014I1
FR11C0014I1 FR11C0014C FR11C0014I1 FR 11C0014 I1 FR11C0014 I1 FR 11C0014I1 FR 11C0014 C FR11C0014 C FR 11C0014C FR 11C0014 I1 FR11C0014 I1 FR 11C0014I1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
French (fr)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of FR11C0014I1 publication Critical patent/FR11C0014I1/fr
Application granted granted Critical
Publication of FR11C0014I2 publication Critical patent/FR11C0014I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR11C0014C 2001-12-12 2011-05-03 Clones d'adn infectieux chimeres de circovirus porcin et utilisation de ceux-ci Active FR11C0014I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US34077501P 2001-12-12 2001-12-12
US42484002P 2002-11-08 2002-11-08
US10/314,512 US7276353B2 (en) 2001-12-12 2002-12-09 Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
PCT/US2002/039646 WO2003049703A2 (en) 2001-12-12 2002-12-11 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof

Publications (2)

Publication Number Publication Date
FR11C0014I1 true FR11C0014I1 (enExample) 2011-06-17
FR11C0014I2 FR11C0014I2 (fr) 2022-03-11

Family

ID=27405726

Family Applications (1)

Application Number Title Priority Date Filing Date
FR11C0014C Active FR11C0014I2 (fr) 2001-12-12 2011-05-03 Clones d'adn infectieux chimeres de circovirus porcin et utilisation de ceux-ci

Country Status (30)

Country Link
US (1) US7276353B2 (enExample)
EP (5) EP1487483B1 (enExample)
JP (1) JP4623964B2 (enExample)
KR (1) KR101014544B1 (enExample)
CN (2) CN1620310B (enExample)
AT (1) ATE487490T1 (enExample)
AU (3) AU2002362147C1 (enExample)
BE (1) BE2011C008I2 (enExample)
BR (1) BRPI0214919B1 (enExample)
CA (2) CA2784260C (enExample)
CO (1) CO5590938A2 (enExample)
CY (3) CY1111167T1 (enExample)
DE (2) DE60238278D1 (enExample)
DK (3) DK2264050T3 (enExample)
ES (3) ES2355814T3 (enExample)
FR (1) FR11C0014I2 (enExample)
HR (3) HRP20140003B1 (enExample)
HU (5) HU230576B1 (enExample)
LT (1) LT2264050T (enExample)
LU (1) LU91814I2 (enExample)
ME (1) ME00126B (enExample)
MX (1) MXPA04005364A (enExample)
NL (1) NL300480I2 (enExample)
NZ (2) NZ533256A (enExample)
PL (3) PL395510A1 (enExample)
PT (3) PT1487483E (enExample)
RS (1) RS51288B (enExample)
SI (3) SI2264050T1 (enExample)
TW (1) TWI314580B (enExample)
WO (1) WO2003049703A2 (enExample)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
CN1749397B (zh) * 2004-08-18 2010-12-08 金宁一 共表达猪圆环病毒及口蹄疫病毒的二联重组活载体疫苗
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
HUE025537T2 (en) 2004-12-30 2016-05-30 Boehringer Ingelheim Vetmedica Inc PCV2-immunogenic compositions and methods for preparing such compositions
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
CN1328373C (zh) * 2005-04-07 2007-07-25 南京农业大学 猪ⅱ型圆环病毒重组腺病毒
NZ564375A (en) * 2005-06-24 2010-02-26 Intervet Int Bv Inactivated chimeric flavivirus vaccines and related methods of use
CA2620727C (en) 2005-09-09 2015-06-16 Intervet International B.V. Porcine circovirus type 2 vaccine
EP1976558B1 (en) * 2005-12-29 2017-03-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 immunogenic composition for lessening clinical symptoms in pigs
HUE054868T2 (hu) * 2005-12-29 2021-10-28 Boehringer Ingelheim Animal Health Usa Inc Multivalens PVC2 immunogén készítmények és eljárások ezek elõállítására
JP4625485B2 (ja) * 2006-09-29 2011-02-02 財団法人大阪産業振興機構 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
US20100136060A1 (en) * 2006-11-22 2010-06-03 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
ES2726777T3 (es) * 2006-12-15 2019-10-09 Boehringer Ingelheim Animal Health Usa Inc Vacuna porcina anti-PCV2 en dosis única
EP1941903A1 (en) * 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
WO2009029130A2 (en) * 2007-05-30 2009-03-05 Wyeth Raccoon poxvirus expressing genes of porcine virus
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
ME01000B (me) * 2007-11-06 2012-10-20 Zoetis Services Llc Živa vakcina avirulentne mycoplasma hyopneumoniae sa adjuvansom
CL2008003813A1 (es) * 2007-12-21 2009-03-20 Zoetis W Llc Circovirus porcino; molecula de acido nucleico que lo codifica; composicion inmunogenica que lo comprende; metodo para inmunizar un cerdo contra la infeccion virica o para prevenir el sindrome postdestete de desgaste multi-sistemico (pmsw);y metodo para determinar si un mamifero tiene o esta en riesgo de desarrollar pmsw.
EP2231182A4 (en) * 2007-12-31 2012-08-22 Boehringer Ingelheim Vetmed PCV2 ORF2 VIRUS TYPE WITH FOREIGN AMINO ACID INSERTION
WO2009126356A2 (en) 2008-01-23 2009-10-15 Boehringer Ingelheim Vetmedica, Inc. Pcv2 mycoplasma hyopneumoniae immunogenic compositions and methods of producing such compositions
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
CN102065890B (zh) * 2008-04-16 2014-04-02 弗吉尼亚科技知识产权公司 嵌合体猪圆环病毒PCV2Gen-1Rep及其用途
TWI627281B (zh) 2009-09-02 2018-06-21 百靈佳殷格翰家畜藥品公司 降低ｐｃｖ－２組合物殺病毒活性之方法及具有改良免疫原性之ｐｃｖ－２組合物
RS59952B1 (sr) 2010-03-16 2020-03-31 Virginia Tech Intellectual Properties Inc Živa atenuisana vakcina protiv himernog svinjskog cirkovirusa
TWI442935B (zh) 2010-12-22 2014-07-01 Sbc Virbac Ltd 豬第二型環狀病毒（Ｐｏｒｃｉｎｅ Ｃｉｒｃｏｖｉｒｕｓ Ｔｙｐｅ ２）、含彼之免疫組合物、檢測套組及其應用
US20130313127A1 (en) 2010-12-28 2013-11-28 The University Of Tokyo Organic compound hydrogenation device and hydrogenation method
HUP1100470A2 (en) * 2011-08-30 2013-03-28 Mezoegazdasagi Biotechnologiai Kutatokoezpont Nanoparticle-based veterinary vaccine
UA113192C2 (xx) 2011-12-06 2016-12-26 Імуногенна композиція проти цирковірусу свиней типу 2 (pcv2)
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
KR102217387B1 (ko) * 2013-03-11 2021-02-19 주식회사 중앙백신연구소 재조합 효모 전세포(yeast whole cell)을 이용한 돼지 써코바이러스(PCV2) 서브유닛 백신과 그의 제조 방법
CA2925281C (en) 2013-09-25 2022-05-03 Zoetis Services Llc Pcv2b divergent vaccine composition and methods of use
EP3052516B1 (en) 2013-10-02 2020-01-01 Boehringer Ingelheim Animal Health USA Inc. Pcv2 orf2 protein variant and virus like particles composed thereof
CN103602759B (zh) * 2013-11-22 2015-09-23 福建省农业科学院畜牧兽医研究所 一种区别鸭圆环病毒和鹅圆环病毒的pcr-rflp方法
ES2771899T3 (es) 2013-12-03 2020-07-07 Intervet Int Bv Vacuna contra circovirus porcino de tipo 2
EA201800494A1 (ru) * 2016-03-07 2019-07-31 Вирджиния Тех Интеллектуал Пропертис, Инк. Вакцины против химерного цирковируса свиней типа 2 (pcv2)
CN106497892A (zh) * 2016-09-07 2017-03-15 扬州大学 带KT3标签的重组病毒rPCV2‑KT3的构建方法
US11957746B2 (en) 2018-03-26 2024-04-16 Boehringer Ingelheim Animal Health USA Inc. Method of producing an immunogenic composition
CN112898435B (zh) * 2021-01-14 2023-03-31 山西农业大学 一种可溶性融合蛋白DT390-Cap及其制备方法与应用
WO2024228148A1 (en) 2023-05-03 2024-11-07 Boehringer Ingelheim Vetmedica Gmbh Immunogenic composition useful for self-administration by pigs
TW202508619A (zh) 2023-05-03 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 用於誘導免疫反應之方法
US20250332242A1 (en) 2024-04-30 2025-10-30 Zoetis Services Llc Porcine endogenous retrovirus (perv)-free porcine circovirus type 2d-based vaccines and methods of use
US20250332243A1 (en) 2024-04-30 2025-10-30 Zoetis Services Llc Methods of manufacturing porcine endogenous retrovirus (perv) free animal health vaccines

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2769321B1 (fr) 1997-10-03 2001-10-26 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
FR2769322B1 (fr) 1997-10-03 2002-03-08 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6391314B1 (en) 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
DE07008633T1 (de) * 1997-12-11 2008-12-18 Merial Virus des multisystemischen Kümmersyndroms bei Absatzferkeln
EP1064024A4 (en) 1998-03-13 2005-04-06 Univ Georgia Res Found VACCINES AGAINST CIRCOVIRUS INFECTIONS
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
US6497883B1 (en) 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
EP1311698A2 (en) 2000-05-03 2003-05-21 University Of Guelph Porcine adenovirus type 5 vector and vaccine
PL360096A1 (en) 2000-05-24 2004-09-06 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
AU2001266940A1 (en) 2000-06-15 2001-12-24 Purdue Research Foundation Vaccine for congenital tremors in pigs
DE10044648A1 (de) 2000-09-08 2002-03-21 Aventis Behring Gmbh Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material
JP4038127B2 (ja) 2001-03-27 2008-01-23 ユニバーシティ オブ サスカチュワン サーコウイルスの培養方法
AUPR567401A0 (en) 2001-06-14 2001-07-12 University Of Melbourne, The Circovirus vaccines

Also Published As

Publication number Publication date
DK1487483T3 (da) 2011-02-21
HRP20040626B1 (hr) 2016-08-26
CA2469599A1 (en) 2003-06-19
RS51704A (sr) 2006-10-27
WO2003049703A3 (en) 2004-09-30
ES2529726T3 (es) 2015-02-25
DE122011100001I1 (de) 2011-09-08
CA2469599C (en) 2012-10-23
LU91814I2 (fr) 2011-07-04
US20030170270A1 (en) 2003-09-11
RS51288B (sr) 2010-12-31
KR101014544B1 (ko) 2011-02-16
HRP20140003B1 (hr) 2020-10-16
NZ533256A (en) 2008-06-30
LT2264050T (lt) 2018-11-26
PL215058B1 (pl) 2013-10-31
CY2011004I2 (el) 2015-10-07
CY1111167T1 (el) 2014-04-09
EP2264050B1 (en) 2018-08-08
SI1487483T1 (sl) 2011-03-31
PL395509A1 (pl) 2011-12-19
EP3388515A1 (en) 2018-10-17
EP1487483A4 (en) 2006-02-15
DE60238278D1 (de) 2010-12-23
SI2264050T1 (sl) 2018-12-31
ES2694505T3 (es) 2018-12-21
HUS2100036I1 (hu) 2021-09-28
JP2005511075A (ja) 2005-04-28
CY2011004I1 (el) 2014-04-09
HU231018B1 (hu) 2019-11-28
PL214803B1 (pl) 2013-09-30
CO5590938A2 (es) 2005-12-30
CY1121112T1 (el) 2019-12-11
ES2355814T3 (es) 2011-03-31
HUP1300097A2 (en) 2007-12-28
CN103536911A (zh) 2014-01-29
TWI314580B (en) 2009-09-11
TW200307042A (en) 2003-12-01
HUP0501000A2 (en) 2007-12-28
EP2263690A3 (en) 2011-06-08
HU231162B1 (hu) 2021-05-28
AU2008202333A1 (en) 2008-06-19
EP1487483B1 (en) 2010-11-10
CN1620310B (zh) 2014-11-26
EP2264050A2 (en) 2010-12-22
AU2002362147A1 (en) 2003-06-23
CA2784260A1 (en) 2003-06-19
EP1487483A2 (en) 2004-12-22
KR20040086243A (ko) 2004-10-08
HRP20140002A2 (hr) 2014-11-07
HK1151988A1 (en) 2012-02-17
NZ567688A (en) 2009-09-25
PL374382A1 (en) 2005-10-17
PT2264050T (pt) 2018-11-21
HRP20040626A2 (en) 2006-03-31
BRPI0214919B1 (pt) 2015-09-15
AU2011200843A1 (en) 2011-03-17
ME00126B (me) 2010-10-10
HU228584B1 (en) 2013-04-29
DK2263689T3 (en) 2015-02-02
EP2263689A2 (en) 2010-12-22
WO2003049703A2 (en) 2003-06-19
AU2002362147C1 (en) 2012-05-17
CA2784260C (en) 2016-05-17
HRP20140002B1 (hr) 2020-10-16
AU2008202333B2 (en) 2010-11-25
BR0214919A (pt) 2006-05-30
PT1487483E (pt) 2011-02-10
US7276353B2 (en) 2007-10-02
BE2011C008I2 (enExample) 2022-02-02
AU2011200843B2 (en) 2012-01-19
JP4623964B2 (ja) 2011-02-02
EP2264050A3 (en) 2011-04-20
EP2263689A3 (en) 2011-04-20
NL300480I2 (enExample) 2016-11-01
HRP20140003A2 (hr) 2014-11-07
MXPA04005364A (es) 2004-09-27
CN1620310A (zh) 2005-05-25
WO2003049703A8 (en) 2005-12-01
AU2002362147B2 (en) 2008-03-13
EP2263690A2 (en) 2010-12-22
PL395510A1 (pl) 2011-12-19
DK2264050T3 (en) 2018-12-03
EP2263689B1 (en) 2014-11-12
ATE487490T1 (de) 2010-11-15
PT2263689E (pt) 2015-02-13
MEP17708A (bs) 2010-06-10
CN103536911B (zh) 2019-09-13
FR11C0014I2 (fr) 2022-03-11
HRP20040626B9 (hr) 2016-09-23
SI2263689T1 (sl) 2015-03-31
HU230576B1 (hu) 2017-01-30

Similar Documents

Publication Publication Date Title
BE2022C547I2 (enExample)
BE2022C502I2 (enExample)
BE2017C059I2 (enExample)
BE2017C057I2 (enExample)
BE2017C051I2 (enExample)
BE2017C032I2 (enExample)
BE2016C051I2 (enExample)
JP2002246600A5 (enExample)
JP2001272923A5 (enExample)
FR11C0014I1 (enExample)
BRPI0209186B1 (enExample)
BE2017C050I2 (enExample)
BRPI0204884B1 (enExample)
HU0202285D0 (enExample)
CH1379220H1 (enExample)
BE2016C021I2 (enExample)
JP2002251164A5 (enExample)
JP2002141882A5 (enExample)
JP2002094398A5 (enExample)
BRPI0101486B8 (enExample)
JP2002046363A5 (enExample)
BRPI0210463A2 (enExample)
JP2002210128A5 (enExample)
JP2002254393A5 (enExample)
JP2001327911A5 (enExample)